IA
PBYI icon

IFP Advisors’s Puma Biotechnology PBYI Stock Holding History

IFP Advisors’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$63.8K Buy
7,863
+955
+14% +$6.99K ﹤0.01% 2250
2026
Q1 		$44.1K Buy
6,908
+6,704
+3,286% +$43.2K ﹤0.01% 2322
2025
Q4 		$1.21K Buy
204
+155
+316% +$823 ﹤0.01% 4009
2025
Q3 		$260 Buy
49
+9
+23% +$38 ﹤0.01% 4343
2025
Q2 		$199 Buy
40
+26
+186% +$83 ﹤0.01% 4630
2025
Q1 		$41 Hold
14
– – ﹤0.01% 4057
2024
Q4 		$43 Buy
+14
New +$41 ﹤0.01% 4301
2021
Q3 		– Sell
-1,463
Closed -$12K – 3434
2021
Q2 		$12K Buy
1,463
+540
+59% +$5.47K ﹤0.01% 2147
2021
Q1 		$8K Buy
923
+128
+16% +$1.43K ﹤0.01% 2235
2020
Q4 		$7K Sell
795
-525
-40% -$5.32K ﹤0.01% 2203
2020
Q3 		$12K Buy
+1,320
New +$13.4K ﹤0.01% 1844
2018
Q3 		– Sell
-2
Closed – – 3965
2018
Q2 		$0 Hold
2
– – ﹤0.01% 4009
2018
Q1 		$0 Hold
2
– – ﹤0.01% 3808
2017
Q4 		$0 Buy
+2
New +$224 ﹤0.01% 4027

Other funds holding PBYI

ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

IFP Advisors's PBYI Position: Q2 2026 in Review

IFP Advisors increased its Puma Biotechnology (PBYI) stake by 14% in Q2 2026, buying an estimated $6.99K and bringing the position to 7,863 shares worth $63.8K. The position accounts for ﹤0.01% of the portfolio, ranked #2250.

IFP Advisors first reported a position in PBYI in Q4 2017 and has held it in 14 quarters since. 160 funds tracked by Wall St. Rank hold PBYI as of Q2 2026.

  • IFP Advisors held 7,863 shares of Puma Biotechnology worth $63.8K as of Q2 2026.
  • IFP Advisors bought 955 Puma Biotechnology shares in Q2 2026, an estimated $6.99K.
  • Puma Biotechnology made up ﹤0.01% of IFP Advisors's portfolio in Q2 2026, its #2250 holding.
  • IFP Advisors first reported a position in Puma Biotechnology in Q4 2017 and has held it in 14 quarters since.
  • 160 funds tracked by Wall St. Rank held Puma Biotechnology as of Q2 2026.

Based on IFP Advisors's 13F filing for Q2 2026, filed 20 Jul 2026.